Evaluation of Serum Asprosin Levels in Patients with T2DM in Duhok District, Iraqi Kurdistan Region


Type 2 diabetes mellitus
Insulin resistance
Metabolic Disorder

How to Cite

Taha, R., & Sulaiman, D. (2022). Evaluation of Serum Asprosin Levels in Patients with T2DM in Duhok District, Iraqi Kurdistan Region. Journal of Life and Bio Sciences Research , 3(02), 51 - 58. https://doi.org/10.38094/jlbsr30273


Asprosin was discovered to be an innovative hormone that is complemented in “adipose tissue” as well as is abnormally elevated in human and mice which are resistant to insulin. Nevertheless, data on the contribution of asprosin in the development of DM (T2DM) is still largely missing. Consequently, the main aim of this trial was to compare the serum asprosin concentration in people with T2DM to those of apparently healthy individuals who reside in Duhok district. This investigation was carried out between Sep. 2021 and Jan. 2022 at “Duhok diabetic center in Azadi teaching and Mazi non-government laboratory”. The levels of serum asprosin were measured in 180 participants (90 confirmed as with T2DM and 90 apparently healthy persons). All of the participants' height, weight, and biochemical variables were measured and compared. Biochemical markers including lipid panel, fasted blood sugar, hemoglobin A1c, and fasted insulin were analyzed via the “auto-analyzer system termed 6000 series COBASS”. While, the blood’s levels of asprosin were calculated through ELISA assay. The study's data was analyzed using “SPSS”. The mean age of adults with T2DM was (43.93 ± 11.95) and among those who appeared to be healthy was (41.09 ± 11.33). Serum asprosin levels were considerably higher in T2DM patients (17.21 ± 4.61) ng/ml than in healthy control (5.17 ± 2.96) (P value < 0.001). In addition, a strong relation existed among serum asprosin and BMI, TG, TCH, FBG, HbA1c, FI, and HOMA-IR (P value < 0.001), whereas an inverse relationship appeared between serum asprosin and HDL-C (P value < 0.01). This investigation proves that adults with T2DM had higher serum asprosin levels than those who seemed to be healthy. Additionally, in individuals with T2DM, serum asprosin was found to be strongly linked with BMI, FBG, FI, HOMAIR, TCH and TG (P value < 0.01).



Ahmed, A.M. (2002). History of diabetes mellitus. Saudi Med. J., 23(4), 373-378.

Alan, M., Gurlek, B., Yilmaz, A., Aksit, M., Aslanipour, B., Gulhan, I., Taner, C.E. (2019). Asprosin: a novel peptide hormone related to insulin resistance in women with polycystic ovary syndrome. Gynecological Endocrinology, 35(3), 220-223.

Ameen, M.R., Sulaiman, D.M., Muho, K.H. (2021). Serum Asprosin levels in women with polycystic ovary syndrome in Duhok city, Kurdistan Region of Iraq. Journal of Life and Bio Sciences Research, 2(2),36-41.

American Diabetes Association (ADA). (2010). Diagnosis and classification of diabetes mellitus. Diabetes Care, 33(Suppl. 1), S62-S69.

Andrade-Oliveira, V., Câ­¡ra, N.O., Moraes-Vieira, P.M. (2015). Adipokines as drug targets in diabetes and underlying disturbances. Journal of Diabetes Research, 2015 (2015), 681612.

Booth, A., Magnuson, A., Fouts, J., Foster, M.T. (2016). Adipose tissue: an endocrine organ playing a role in metabolic regulation. Hormone Molecular Biology and Clinical Investigation, 26(1), 25-42.

Chatterjee, S., Khunti, K., Davies, M.J. (2017). Type 2 diabetes. The Lancet, 389(10085), 2239-51.

Clark, M., Hoenig, M. (2016). Metabolic effects of obesity and its interaction with endocrine diseases. Veterinary Clinics: Small Animal Practice, 46(5), 797-815.

Czech, M.P. (2017). Insulin action and resistance in obesity and type 2 diabetes. Nature medicine, 23(7), 804-814.

DeFronzo, R.A., Ferrannini, E., Groop, L., Henry, R.R., Herman, W.H., Holst, J.J., Hu, F.B., Kahn, C.R., Raz, I., Shulman, G.I. Simonson, D.C. (2015). Type 2 diabetes mellitus. Nature Reviews Disease Primers, 1(1), 1-22.

Deng, X., Zhao, L., Guo, C., Yang, L., Wang, D., Li, Y., Yuan, G. (2020). Higher serum asprosin level is associated with urinary albumin excretion and renal function in type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 13, 4341-51.

Deniz, R., Yavuzkir, S., Ugur, K., Ustebay, D.U., Baykus, Y., Ustebay, S., Aydin, S. (2021). Subfatin and asprosin, two new metabolic players of polycystic ovary syndrome. Journal of Obstetrics and Gynaecology, 41(2), 279-284.

Deore, D.N., Surwase, S.P., Masroor, S., Khan, S.T., Kathore, V. (2012). A Cross sectional study on the relationship between the Body Mass Index (BMI) and the Audiovisual Reaction Time (ART). Journal of Clinical and Diagnostic Research, 6(9), 1466-8.

Duerrschmid, C., He, Y., Wang, C., Li, C., Bournat, J.C., Romere, C., Romere, C. (2017). Asprosin is a centrally acting orexigenic hormone. Nat Med, 23(12), 1444-53.

Garvey, W.T., Garber, A.J., Mechanick, J.I., Bray, G.A., Dagogo-Jack, S., Einhorn, D., Grunberger, G., Handelsman, Y., Hennekens, C.H., Hurley, D.L., McGill, J. (2014). The American association of clinical endocrinologists and American college of endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. Endocr. Pract., 20(9), 977-89.

Gozel, N., Kilinc, F. (2021). Investigation of plasma asprosin and saliva levels in newly diagnosed diabetes mellitus patients treated with metformin. Endokrynol Pol., 72(1), 37-43.

Groener, J.B., Valkanou, A., Kender, Z., Pfeifenberger, J., Kihm, L., Fleming, T. (2019). Asprosin response in hypoglycemia is not related to hypoglycemia unawareness but rather to insulin resistance in type 1 diabetes. PLOS ONE, 14(9), e0222771.

Hekim, M.G., Kelestemur, M.M., Bulmus, F.G., Bilgin, B., Bulut, F., Gokdere, E., Ozdede, M.R., Kelestimur, H., Canpolat, S., Ozcan, M. (2021). Asprosin, a novel glucogenic adipokine: a potential therapeutic implication in diabetes mellitus. Archives of Physiology and Biochemistry, 1, 1-7.

Hoffmann, J.G., Xie, W., Chopra, A.R. (2020). Energy Regulation Mechanism and Therapeutic Potential of Asprosin. Diabetes, 69(4), 559-66.

Kassaian, S.E., Goodarzynejad, H., Boroumand, M.A., Salarifar, M., Masoudkabir, F., Mohajeri-Tehrani, M.R., Pourhoseini, H., Sadeghian, S., Ramezanpour, N., Alidoosti, M., Hakki, E., Saadat, S., Nematipour, E. (2012). Glycosylated hemoglobin (HbA1c) levels and clinical outcomes in diabetic patients following coronary artery stenting. Cardiovasc Diabetol, 11(82), 1-10.

Ke, X., Duan, L., Gong, F., Zhang, Y., Deng, K., Yao, Y., Wang, L., Pan, H. Zhu, H. (2020). Serum levels of asprosin, a novel adipokine, are significantly lowered in patients with acromegaly. International Journal of Endocrinology, 2020, 1-10.

Kocaman, N., Kulolu, T. (2020). Expression of asprosin in rat hepatic, renal, heart, gastric, testicular and brain tissues and its changes in a streptozotocin-induced diabetes mellitus model. Tissue and Cell, 66, 101397.

Lee, T., Yun, S., Jeong, J. H., Jung, T.W. (2019). Asprosin impairs insulin secretion in response to glucose and viability through TLR4/JNK-mediated inflammation. Molecular and Cellular Endocrinology, 486, 96-104.

Leonard, A. N., Shill, A. L., Thackray, A. E., Stensel, D.J., Bishop, N.C. (2021). Fasted plasma asprosin concentrations are associated with menstrual cycle phase, oral contraceptive use and training status in healthy women. European Journal of Applied Physiology, 121(3), 793-801.

Li, X., Liao, M., Shen, R., Zhang, L., Hu, H., Wu, J., Zheng, H. (2018). Plasma asprosin levels are associated with glucose metabolism, lipid, and sex hormone profiles in females with metabolic-related diseases. Mediators of Inflammation, 6, 2018, 7375294.

Luis, C., Fernandes, R., Soares, R., von Hafe, P. (2020). A state of the art review on the novel mediator asprosin in the metabolic syndrome. Porto Biomedical Journal, 5(6), e108.

Mazur-Bialy, A.I. (2021). Asprosin-A fasting-induced, glucogenic, and orexigenic adipokine as a new promising player. will it be a new factor in the treatment of obesity, diabetes, or infertility? A review of the literature. Nutrients, 13(2), 620.

Naiemian, S., Naeemipour, M., Zarei, M., Lari Najafi, M., Gohari, A., Behroozikhah, M.R., Miri, M. (2020). Serum concentration of asprosin in new-onset type 2 diabetes. Diabetology & Metabolic Syndrome,12(1),1-8.

Olokoba, A.B., Obateru, O.A., Olokoba, L.B. (2012). Type 2 Diabetes Mellitus: A Review of Current Trends. Oman Medical Journal, 27(4), 269-273.

O'Neill, S., O'Driscoll, L. (2015). Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obesity Reviews, 16(1), 1-12.

Park, S.E., Park, C.Y., Sweeney, G. (2015). Biomarkers of insulin sensitivity and insulin resistance: Past, present and future. Crit. Rev. Clin. Lab. Sci., 52(4), 180-90.

Rojas, J., Chᶥz, M., Olivar, L., Rojas, M., Morillo, J., Mejí¡³, J., Calvo, M. Berm V. (2014). Polycystic ovary syndrome, insulin resistance, and obesity: navigating the pathophysiologic labyrinth. International Journal of Reproductive Medicine, 2014, 719050.

Romere, C., Duerrschmid, C., Bournat, J., Constable, P., Jain, M., Xia, F., Saha, P.K., Del Solar, M., Zhu, B., York, B., Sarkar, P. (2016). Asprosin, a fasting-induced glucogenic protein hormone. Cell., 165(3), 566-79.

Sami, W., Ansari, T., Butt, N.S., Ab Hamid, M.R. (2017). Effect of diet on type 2 diabetes mellitus: A review. International Journal of Health Sciences, 11(2), 65-71.

Silistre, E., Hatipogl, H.U. (2020). Increased serum circulating asprosin levels in children with obesity. Pediatr Int, 62(4), 467-76.

Sulaiman, DM. (2021). Evaluation of serum asprosin levels in women with metabolic syndrome in Duhok City-Kurdistan Region/Iraq. International Journal of Research in Medical Sciences, 9(8), 2240-45.

Thewjitcharoen, Y., Jones Elizabeth, A., Butadej, S., Nakasatien, S., Chotwanvirat, P., Wanothayaroj, E., Krittiyawong, S., Himathongkam, T. Himathongkam, T. (2019). Performance of HbA1c versus oral glucose tolerance test (OGTT) as a screening tool to diagnose dysglycemic status in high-risk Thai patients. BMC Endocrine Disorders, 19(1), 1-8.

Titchenell, P.M., Lazar, M.A., Birnbaum, M.J. (2017). Unraveling the regulation of hepatic metabolism by insulin. Trends in Endocrinology & Metabolism, 28(7), 497-505.

Ugur, K., Aydin, S. (2019). Saliva and blood asprosin hormone concentration associated with obesity. Int J Endocrinol, 2019, 2521096.

Wang, M., Yin, C., Wang, L., Liu, Y., Li, H., Li, M. (2019). Serum asprosin concentrations are increased and associated with insulin resistance in children with obesity. Ann. Nutr. Metab., 75, 205-12.

Wang, Y., Qu, H., Xiong, X., Qiu, Y., Liao, Y., Chen, Y. (2018). Plasma asprosin concentrations are increased in individuals with glucose dysregulation and correlated with insulin resistance and first-phase insulin secretion. Mediators Inflamm., 2018, 9471583.

Wu, L., Parhofer, K.G. (2014). Diabetic dyslipidemia. Metabolism, 63(12), 1469-79.

Yuan, M., Li, W., Zhu, Y., Yu, B., Wu, J. (2020). Asprosin: A novel player in metabolic diseases. Front Endocrinol, 11, 64.

Zhang, H., Hu, W., Zhang, G. (2020b). Circulating asprosin levels are increased in patients with type 2 diabetes and associated with early-stage diabetic kidney disease. Int. Urol. Nephro., 52(8), 1517-22.

Zhang, L., Chen, C., Zhou, N., Fu, Y., Cheng, X. (2019). Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride. Clin. Chim. Acta, 489, 183-188.

Zhang, X., Jiang, H., Ma, X., Wu, H. (2020a). Increased serum level and impaired response to glucose fluctuation of asprosin is associated with type 2 diabetes mellitus. Journal of Diabetes Investigation, 11(2), 349-355.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Copyright (c) 2022 Array